title: Immunological selection for Leishmania (Viannia) braziliensis antigens.
abstract: Comparative ELISA and selective immunoblotting procedures were used in attempts to identify differential serological indicators of infection with the Leishmania (Viannia) braziliensis complex, infection with the L. braziliensis species, and therapeutic cure of localized or mucocutaneous leishmaniasis (LCL or MCL). Although mean ELISA absorbance values were significantly higher for MCL sera than for LCL sera, absorbance could not be used as a reliable indicator of the clinical form of disease. Immunoblotting profiles were similar with sera from MCL and LCL. Pre-adsorption with heterologous trypanosomatid antigens indicated that recognition of antigens of about 56, 60, 66, 72, 88 and 110 kDa might be specific to the subgenus Viannia. In two-colour, sequential, dual ELISA-based immunoblotting, no antigens recognized only by sera from MCL patients were detected. After glucantime therapy, immunoblotting profiles with LCL sera were reduced both in intensity and in the range of antigens detected; a 104-kDa antigen was newly detected with post-treatment LCL sera. Overall, the results show the value of differential immunological detection strategies and support the close relationship between species of the subgenus Viannia but fail to indicate a prognostic antigen for MCL.
authors.affiliation: Department of Pathology, University of Brasilia, Brasilia, DF 70910.900, Brazil.
authors.forename: C A
authors.initials: CA
authors.lastname: Cuba Cuba
authors.forename: W
authors.initials: W
authors.lastname: Ogunkolade
authors.forename: M K
authors.initials: MK
authors.lastname: Howard
authors.forename: M A
authors.initials: MA
authors.lastname: Miles
mesh_terms: D000818:Animals; D000953:Antigens, Protozoan / Q000187:drug effects / Q000276:immunology*; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D015153:Blotting, Western; D016022:Case-Control Studies; D003429:Cross Reactions; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007892:Leishmania braziliensis / Q000187:drug effects / Q000276:immunology*; D007897:Leishmaniasis, Mucocutaneous / Q000188:drug therapy / Q000276:immunology*; D008536:Meglumine / Q000627:therapeutic use; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000627:therapeutic use
chemical_list: D000953:Antigens, Protozoan; D000981:Antiprotozoal Agents; D015415:Biomarkers; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate